



Condensed Interim Consolidated Financial Statements
For the three and six months ended October 31, 2018 and 2017



Condensed Interim Consolidated Statements of Financial Position

As at:

(unaudited)

<i>In thousands of US dollars</i>	Notes	October 31, 2018	April 30, 2018
Assets			
Current assets:			
Cash		\$ 5,935	\$ 121
Prepaid expenses and deposits		534	494
Investment tax credit receivable		156	98
Other assets		95	157
Clinical supplies		2,286	3,056
Due from related parties		250	118
Total current assets		9,256	4,044
Non-current assets:			
Property and equipment		408	468
Intangible assets		2,282	2,181
Prepaid expenses and deposits		103	104
Deferred financing costs		2	214
Clinical supplies		560	1,267
Total non-current assets		3,355	4,234
Total assets		\$ 12,611	\$ 8,278
Liabilities			
Current liabilities:			
Trade and other payables		\$ 6,827	\$ 22,204
Accrued interest		167	-
Promissory notes		312	708
Unearned licensing rights fee		6,077	6,230
Warrant liability	7 (e)	46,476	8,813
Debt	5	18,452	-
Total current liabilities		78,311	37,955
Non-current liabilities:			
Royalty preferred shares	6	90,100	54,000
Total liabilities		168,411	91,955
Shareholders' equity (deficit):			
Share capital	7 (a)	265,108	249,589
Contributed surplus		40,732	39,640
Warrants	7 (f)	1,229	1,269
Deficit		(462,869)	(374,175)
Total shareholders' equity (deficit)		(155,800)	(83,677)
Total liabilities and shareholders' equity (deficit)		\$ 12,611	\$ 8,278
Future operations (note 3)	Commitments (note 9)	Subsequent event (note 10)	
Signed on behalf of the Board:			
Signed:	<u>"Dr. Eldon Smith"</u>	Director	Signed: <u>"Kenneth Zuerblis"</u> Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Comprehensive Loss
For the three and six months ended October 31
(unaudited)

<i>In thousands of US dollars</i>	Notes	Three months ended October 31,		Six months ended October 31,	
		2018	2017	2018	2017
Expenses:					
Research and development, net of recoveries	8	\$ 8,939	\$ 8,447	\$ 15,622	\$ 16,504
Investment tax credits		(31)	(7)	(61)	(40)
Net research and development		8,908	8,440	15,561	16,464
General and administrative, net of recoveries	8	2,000	1,141	3,007	2,026
		10,908	9,581	18,568	18,490
Finance costs (income):					
Loss (gain) on change in fair value of warrant liability	7 (e)	14,591	(1,471)	30,969	(3,567)
Loss on change in fair value of royalty preferred shares	6	12,200	2,400	36,100	3,900
Interest, fees and accretion		1,403	2,253	2,898	4,190
Financing costs		178	137	337	245
Foreign exchange (gain) loss		(81)	(2,038)	(182)	2,951
Net finance costs		28,291	1,281	70,122	7,719
Loss before income taxes		39,199	10,862	88,690	26,209
Income taxes		4	13	4	22
Net and total comprehensive loss		\$ 39,203	\$ 10,875	\$ 88,694	\$ 26,231
Net loss per share (note 7 (g))					
Basic and diluted		\$ 0.21	\$ 0.10	\$ 0.49	\$ 0.24

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Deficit)
For the six months ended October 31
(unaudited)

<i>In thousands of US dollars</i>	Share Capital	Contributed Surplus	Warrants	Deficit	Total Shareholders' Deficit
Balance, April 30, 2017	\$ 174,622	\$ 39,234	\$ 440	\$ (315,865)	\$ (101,569)
Common shares issued in connection with private placement	6,438	-	-	-	6,438
Common shares issued in connection with prospectus offering	2,714	-	-	-	2,714
Common shares issued in connection with stock option and long term incentive plans	109	(54)	-	-	55
Share issue cost	(443)	-	-	-	(443)
Warrants issued in connection with prospectus offering	-	-	41	-	41
Share-based payment transactions	-	155	-	-	155
Net and total comprehensive loss	-	-	-	(26,231)	(26,231)
Balance, October 31, 2017	\$ 183,440	\$ 39,335	\$ 481	\$ (342,096)	\$ (118,840)
Balance, April 30, 2018	\$ 249,589	\$ 39,640	\$ 1,269	\$ (374,175)	\$ (83,677)
Common shares issued in connection with private placement	13,686	-	-	-	13,686
Common shares issued in connection with stock option and long term incentive plans	506	(277)	-	-	229
Share issue cost	(386)	-	-	-	(386)
Common shares issued in connection with warrant exercises	1,713	-	(40)	-	1,673
Share-based payment transactions	-	1,369	-	-	1,369
Net and total comprehensive loss	-	-	-	(88,694)	(88,694)
Balance, October 31, 2018	\$ 265,108	\$ 40,732	\$ 1,229	\$ (462,869)	\$ (155,800)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Condensed Interim Consolidated Statements of Cash Flows
For the six months ended October 31
(unaudited)

<i>In thousands of US dollars</i>	2018	2017
Cash provided by (used in):		
Cash flows provided by (used in) operating activities:		
Net loss	\$ (88,694)	\$ (26,231)
Items not involving cash:		
Equity-settled share-based payment transactions	1,369	155
Depreciation and amortization	172	190
Change in fair value of warrant liability	30,969	(3,567)
Change in fair value of royalty preferred shares	36,100	3,900
Impairment of intangible assets	-	294
Unrealized foreign exchange	-	2,925
Interest, fees and accretion	2,898	4,190
Net current income taxes	4	22
Changes in non-cash working capital:		
Prepaid expenses and deposits	(39)	(704)
Investment tax credit receivable	(58)	(46)
Other assets	62	(78)
Clinical supplies	1,477	670
Due from related parties	(132)	187
Unearned licensing rights fee	(153)	6,200
Trade and other payables	(15,169)	(250)
	(31,194)	(12,143)
Interest received	26	1
Financing costs	337	150
Income tax paid	(7)	(40)
Net cash used in operating activities	(30,838)	(12,032)
Cash flows generated from financing activities:		
Proceeds from Third Eye Capital loan	30,000	-
Debt issuance costs	(1,287)	-
Financing costs	(236)	(150)
Proceeds from equity units issued in connection with private placements	20,000	8,229
Proceeds from equity units issued in connection with prospectus offering	-	3,464
Share issuance costs	(386)	(363)
Deferred financing costs, net of recovery	(2)	16
Proceeds from exercise of stock options	228	55
Proceeds from exercise of warrants	634	-
Partial repayment of Third Eye Capital loan	(10,313)	-
Interest and fees paid	(1,162)	(8)
Repayment of promissory note	(397)	-
Changes in non-cash financing working capital	(23)	242
Net cash generated from financing activities	37,056	11,485
Cash flows used in investing activities:		
Property and equipment additions	(3)	-
Intangible asset additions	(210)	(206)
Changes in non-cash investing working capital	(188)	82
Net cash used in investing activities	(401)	(124)
Effect of foreign currency translation on cash	(3)	27
Increase (decrease) in cash	5,814	(644)
Cash, beginning of period	121	1,355
Cash, end of period	\$ 5,935	\$ 711

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and six months ended October 31, 2018 and 2017

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

1. General information

Resverlogix Corp. (the “Company”) is a company domiciled in Canada. The condensed interim consolidated financial statements comprise the Company and its wholly-owned subsidiary Resverlogix Inc. (together referred to as “Resverlogix” or the “Group”). Resverlogix Corp. is incorporated under the laws of Alberta. Resverlogix Inc. is incorporated under the laws of Delaware. The Company’s head office is located at Suite 300, 4820 Richard Road S.W., Calgary, Alberta, T3E 6L1. The registered and records office is located at Suite 600, 815 - 8th Avenue S.W., Calgary, Alberta, T2P 3P2.

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease, and, other orphan diseases while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in 13 countries worldwide, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). The Company is considered to be in the development stage, as most of its efforts have been devoted to research and development and it has not earned any revenue to date.

2. Basis of preparation

(a) Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with IAS 34 – *Interim Financial Reporting*. These condensed interim consolidated financial statements were approved and authorized for issue by the Board of Directors on December 11, 2018.

Certain information, in particular the accompanying notes normally included in the annual financial statements prepared in accordance with IFRS, has been omitted or condensed. These condensed interim consolidated financial statements do not include all disclosures required under IFRS and, accordingly, should be read in conjunction with the annual financial statements for the year ended April 30, 2018 and the notes thereto prepared in accordance with International Financial Reporting Standards (“IFRS”) as prescribed by the International Accounting Standards Board (“IASB”).

(b) Basis of measurement

The consolidated financial statements have been prepared on the historical cost basis except for the revaluation of the liability classified warrants and liability classified royalty preferred shares, which are measured at fair value each reporting period. Debt is measured initially at fair value and subsequently at amortized cost. Historical cost is based on the fair value of the consideration given in exchange for assets recorded on the date of the transaction.

(c) Functional and presentation currency

The functional currency of all entities within the Group is the US dollar, which is also the presentation currency. All financial information presented in dollars has been rounded to the nearest thousand except for per share amounts.

(d) Use of estimates and judgment

The preparation of the condensed interim consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the amounts reported in these condensed interim consolidated financial statements and notes. Accordingly, actual results may differ from estimated amounts as future confirming events occur. Significant estimates and judgment used in the preparation of the condensed interim consolidated financial statements remain unchanged from those described in the Group’s consolidated financial statements for the year ended April 30, 2018.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and six months ended October 31, 2018 and 2017

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

3. Future operations

The success of the Company is dependent on the continuation of its research and development activities, progressing the core technologies through clinical trials to commercialization and its ability to finance its cash requirements.

It is not possible to predict the outcome of future research and development programs, the Company's ability to fund these programs in the future, or the commercialization of products by the Company.

The consolidated financial statements have been prepared pursuant to International Financial Reporting Standards applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they come due. The Company has incurred significant losses to date, and with no assumption of revenues, is dependent on its ability to raise additional financial capital by continuing to demonstrate the successful progression of its research and development activities if it is to remain as a going concern.

As at October 31, 2018, the Company had \$5.9 million of cash and was committed to pay \$6.8 million of trade and other payables, \$7.2 million for research and development, and \$0.7 million of lease obligations over the next twelve months as described further in Note 9. In addition, expenditures over the next twelve months under cancellable agreements with contract research organizations and central laboratories conducting the BETonMACE and other trials were estimated to total approximately \$15 – 20 million. Also, the Company may have to repay the CAD\$8.0 million unearned licensing rights fee, unless it is credited against payment obligations of Hepalink USA Inc. pursuant to a license agreement, as described in Note 10 of the Company's consolidated financial statements for the year ended April 30, 2018.

As described in Note 5, during the six months ended October 31, 2018, the Company closed a US\$30.0 million senior secured loan (the "Third Eye Loan") with Third Eye Capital ("Third Eye"). The loan bears interest at 10% per annum and will mature on May 4, 2019. Pursuant to the loan agreement with Third Eye the Company must maintain a cash balance greater than \$5 million, a current ratio greater than 1:1 (excluding warrant liability, unearned licensing rights fee and debt from current liabilities), and a market capitalization greater than CAD\$150 million, as well as other customary covenants. The Third Eye Loan is subject to mandatory prepayment provisions requiring at least 50% of the net cash proceeds of asset dispositions, licensing, distribution or partnership agreements, royalties, debt or equity issuances, grants and tax refunds to be applied to repayment of the Third Eye Loan. During the six months ended October 31, 2018, the Company repaid \$10.3 million of the Third Eye Loan, corresponding to 50% of the net cash proceeds from the private placement and warrant exercises in the period. In addition, as described in Note 10, subsequent to October 31, 2018, the Company closed a \$10.3 million private placement. The Company then repaid \$5.15 million of the Third Eye Loan corresponding to 50% of the net cash proceeds from the \$10.3 million private placement.

The Company's cash as at October 31, 2018, in addition to the \$10.3 million raised subsequent to October 31, 2018, will not be sufficient to fund the Company's contractual commitments or the Company's planned business operations over the next year and repay the Third Eye Loan or comply with the loan covenants. Therefore, the Company will have to raise additional capital to fund its contractual commitments and its planned business operations, and to continue to comply with its loan covenants. The Company continues to pursue and/or examine both non-dilutive and dilutive arrangements, with a preference for non-dilutive alternatives, including co-development, licensing, rights (on indications or potential follow-on compounds) or other partnering arrangements, private placements and/or public offerings (equity and/or debt). However, there is no assurance that any of these measures will be completed.

These conditions result in a material uncertainty which may cast significant doubt on the Company's ability to continue as a going concern. If the Company is not able to raise capital, the Company will also have to reduce its cash requirements by eliminating or deferring spending on research, development and corporate activities, or may be forced to cease operations.

The Company will also require additional capital to fund research, development and corporate activities beyond the next year. The Company will continue to explore alternatives to generate additional cash including raising additional equity and/or debt and/or partnering; however, there is no assurance that these initiatives will be successful.

These financial statements do not include any adjustments to the amounts and classifications of assets and liabilities, and the reported expenses that might be necessary should the Company be unable to continue as a going concern.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and six months ended October 31, 2018 and 2017

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

4. Significant accounting policies

The condensed interim consolidated financial statements should be read in conjunction with the Company's annual consolidated financial statements for the year ended April 30, 2018 prepared in accordance with IFRS applicable to those annual consolidated financial statements. The same accounting policies, presentation and methods of computation have been followed in these condensed interim consolidated financial statements as were applied in the Company's consolidated financial statements for the year ended April 30, 2018.

New standards and interpretations adopted

The Company has adopted the following new standard, with a date of initial application of May 1, 2018:

IFRS 9 – Financial Instruments

IFRS 9 – *Financial Instruments* (“IFRS 9”) replaces IAS 39 – *Financial Instruments: Recognition and Measurement* for annual periods beginning on or after January 1, 2018. IFRS 9 includes guidance on the classification and measurement of financial assets and impairment of financial assets. The Company has applied IFRS 9 retrospectively, with the initial application date of May 1, 2018. There were no changes to the measurement of the Company's financial assets and liabilities or adjustments to comparative information as a result of the adoption of IFRS 9.

Recent accounting pronouncements

IFRS 16 – Leases

On January 13, 2016, the IASB issued IFRS 16 – *Leases* which replaces IAS 17. The new standard introduces a single lessee accounting model and requires a lessee to recognize a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. This standard substantially carries forward the lessor accounting requirements of IAS 17, while requiring enhanced disclosures to be provided by lessors. Other areas of the lease accounting model have been impacted, including the definition of a lease.

Resverlogix will adopt IFRS 16 on May 1, 2019, and has selected the modified retrospective transition approach. Resverlogix has also elected to apply the optional exemptions for short-term and low-value leases. IFRS 16 is expected to increase the Corporation's assets and liabilities, increase depreciation expense, increase interest, accretion and finance costs and reduce general and administrative expenses and research and development expenses. Cash payments associated with operating leases are currently presented within operating activities; under IFRS 16, the cash flows will be allocated between financing activities for the repayment of the principal liability and operating activities for the financing expense portion. The overall impact to cash flow will be unchanged. Management is still quantifying the impact of IFRS 16 adoption.

5. Debt

	October 31, 2018	April 30, 2018
US\$30.0 million (initial principal), 10% due May 4, 2019	\$ 19,687	\$ -
Unamortized transaction costs, net of accretion	(1,513)	-
Exit fee, net of accretion	278	-
Carrying value of debt	\$ 18,452	\$ -

Third Eye Capital Loan

On May 4, 2018 the Company closed a US\$30.0 million senior secured loan (the “Third Eye Loan”) with Third Eye Capital (“Third Eye”). The loan bears interest at 10% per annum, calculated and payable monthly in arrears, and will mature on May 4, 2019. Pursuant to the loan agreement with Third Eye, the borrower covenants the Company must comply with include: maintaining a cash balance greater than \$5 million, a current ratio greater than 1:1 (excluding warrant liability, unearned licensing rights fee and debt from current liabilities), and a market capitalization greater than CAD\$150 million (as of the last trading day of each month), as well as other customary covenants. The Third Eye Loan is subject to mandatory prepayment provisions requiring at least 50% of the net cash proceeds of asset dispositions, licensing, distribution or partnership agreements, royalties, debt or equity issuances, grants and tax refunds to be applied to repayment of the Third Eye Loan. During the six months ended

Notes to the Condensed Interim Consolidated Financial Statements

For the three and six months ended October 31, 2018 and 2017

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

5. Debt (continued)

October 31, 2018, the Company repaid \$10.3 million of the Third Eye Loan, corresponding to 50% of the net cash proceeds from the private placement and warrant exercises in the period. In addition, as described in Note 10, subsequent to October 31, 2018, the Company closed a \$10.3 million private placement. The Company then repaid \$5.15 million of the Third Eye Loan corresponding to 50% of the net cash proceeds from the \$10.3 million private placement subsequent to October 31, 2018. The Company is in compliance with the Third Eye Loan debt covenants as at October 31, 2018.

Interest for approximately the first four months of the term (\$1.0 million of non-refundable interest) was pre-paid in advance at closing pursuant to the terms of the Third Eye Loan. The Company paid to Third Eye a one-time commitment fee of \$0.9 million and is obligated to pay a \$0.6 million exit fee upon full and final repayment or termination of the Third Eye Loan. As well, the Company issued 3.5 million warrants to Third Eye in connection with the Third Eye Loan. Each warrant is exercisable at a price of CAD\$1.40 per underlying common share for a period of three years from the closing of the Third Eye Loan.

6. Royalty preferred shares

(i) Authorized:

Unlimited number of royalty preferred shares issuable in series with rights as determined by the Board of Directors at the time of issue.

(ii) Issued and outstanding:

Preferred shares	Number of shares	Amount
Balance, April 30, 2017	75,202,620	\$ 42,700
Revaluation of royalty preferred shares	-	11,300
Balance, April 30, 2018	75,202,620	54,000
Revaluation of royalty preferred shares	-	36,100
Balance, October 31, 2018	75,202,620	\$ 90,100

As at October 31, 2018, the Company had 75,202,620 royalty preferred shares outstanding, all of which were held by Zenith. For fair value measurement purposes, the royalty preferred shares liability has been categorized within level 3 of the fair value measurement hierarchy. The fair value of the royalty preferred shares is based on management's judgments, estimates and assumptions which include significant unobservable inputs including the timing and amounts of the Company's discounted risk adjusted future net cash flows. The estimate incorporates the following assumptions: a cumulative probability rate of generating forecasted future cash flows of 42% as at October 31, 2018 (April 30, 2018 - 35%) reflecting in each case, among other factors, the Company's clinical results and communication with regulatory bodies; a discount rate of 20.4% as at October 31, 2018 (April 30, 2018 - 21.7%); commencement of revenue beginning between late 2021 and 2022 (based on clinical development paths across various jurisdictions) as at October 31, 2018 (April 30, 2018 - between late 2021 and 2023); apabetalone market share percentages; and product pricing.

On June 14, 2018 the Company announced that it had received confirmation from the U.S. Food and Drug Administration ("FDA") that the Company's on-going Phase 3 study, if successful, is likely to support the filing and approval of a New Drug Application ("NDA"). As at October 31, 2018, management updated the estimated fair value to: reflect the reduced length of time (due to the passage of time) from October 31, 2018 to future cash flows based on the estimated timing and commencement of revenue, to decrease the discount rate due to a decrease in the estimated size premium rate (a component of the Company's estimated weighted average cost of capital), and to reflect the increased cumulative probability rate of generating forecasted future cash flows (to reflect the FDA communication that the BETonMACE study, if successful, is likely to support the filing and approval of an NDA).

The fair value of the royalty preferred shares is subject to significant volatility. Small changes in the aforementioned assumptions may have a significant impact on the fair value of the royalty preferred shares. For instance, holding all other assumptions constant, a 1% increase in the discount rate would result in a \$7.5 million decrease in the fair value of the royalty preferred shares. Furthermore, assuming commencement of revenue one year later would result in a \$20.2 million decrease in the fair value of the royalty preferred shares.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and six months ended October 31, 2018 and 2017

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit)

(a) Common shares

(i) Authorized:

Unlimited number of common shares

(ii) Issued and outstanding:

Common shares	Number of shares	Amount
Balance, April 30, 2017	105,642,444	\$ 174,622
Issued in connection with private placements	68,927,960	74,925
Issued in connection with prospectus offering	2,552,489	2,714
Issued in connection with stock option plan	63,099	113
Share issue cost	-	(2,785)
Balance, April 30, 2018	177,185,992	249,589
Issued in connection with private placement	10,403,216	13,686
Issued in connection with warrant exercises	701,141	1,713
Issued in connection with stock option plan	217,984	456
Issued in connection with long term incentive plan	41,666	50
Share issue cost	-	(386)
Balance, October 31, 2018	188,549,999	\$ 265,108

Private placements and prospectus offering

On June 20, 2017, the Company issued a total of \$7.5 million (CAD\$10 million) of equity units pursuant to a private placement and prospectus offering. Eastern Capital Limited ("Eastern") and Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink") purchased 1,617,980 and 1,333,333 equity units, respectively at a price of CAD\$1.80 per unit pursuant to a private placement for gross proceeds of \$4.0 million (CAD\$5.3 million). Other subscribers purchased an additional 2,552,489 equity units at a price of CAD\$1.80 per unit pursuant to a prospectus offering for gross proceeds of an additional \$3.5 million (CAD\$4.6 million). Each equity unit consists of one common share and one common share purchase warrant. Each warrant is exercisable at a price of CAD\$2.05 per underlying common share for a period of four years from the closing of the private placement and prospectus offering.

On September 8, 2017, the Company issued 3,418,744 equity units, consisting of one common share and one half common share purchase warrant, at CAD\$1.50 per unit pursuant to a private placement for gross proceeds of \$4.2 million (CAD\$5.1 million).

On December 1, 2017, the Company issued 60,416,667 equity units to Hepalink at CAD\$1.44 per unit pursuant to a private placement for gross proceeds of \$68.5 million (CAD\$87.0 million). Each equity unit consists of one common share and 0.082759 of a common share purchase warrant. Each warrant is exercisable at a price of CAD\$1.64 per underlying common share for a period of four years from the closing of the private placement.

On April 12, 2018 the Company issued 364,914 equity units at CAD\$1.75 per unit pursuant to a private placement for gross proceeds of \$0.5 million (CAD\$0.6 million). Each unit consists of one common share and one-half of a common share purchase warrant. Each warrant is exercisable at a price of CAD\$2.00 per underlying common share for a period of two years from the closing of the private placement.

During the three months ended April 30, 2018, the Company issued 1,776,322 shares at a weighted average price of CAD\$1.78 pursuant to additional private placements for gross proceeds of \$2.5 million (CAD\$3.2 million).

Notes to the Condensed Interim Consolidated Financial Statements

For the three and six months ended October 31, 2018 and 2017

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit) (continued)

(a) Common shares (continued)

In August 2018, the Company issued 10,403,216 equity units at CAD\$2.50 per unit pursuant to a private placement for gross proceeds of \$20.0 million (CAD\$26.0 million). Each unit consists of one common share and one-half of a common share purchase warrant. Each warrant is exercisable at a price of CAD\$3.00 per underlying common share for a period of three years from the closing of the private placement.

Share issue costs

During the six months ended October 31, 2018, the Company recognized total share issue costs of \$0.4 million. During the year ended April 30, 2018, the Company recognized total share issue costs of \$2.8 million, including \$0.8 million associated with warrants issued to the financial advisor involved with the December 1, 2017 private placement, as described in Note 7 (f).

(b) Stock options

The Company's amended stock option plan has been approved as a rolling 10% plan that allows for reservation of a number of common shares under the plan equal to 10% of the Company's issued and outstanding common shares on an undiluted basis. Additionally, the plan is a reloading plan, which allows for the number of common shares reserved for issuance related to the options under the plan to automatically become eligible to be reallocated pursuant to stock option based grants upon option expiry, cancellation or exercise. The Company may grant options to its directors, officers, employees and consultants.

The majority of options fully vest over one to three years and have a five year term. Certain stock options have performance conditions which must be satisfied in order for the options to vest. The options are settled by way of the issuance of equity instruments of the Company ("equity-settled").

	Number of options	Weighted average exercise price (CAD)
Outstanding, April 30, 2017	3,449,499	\$ 1.77
Exercised	(63,099)	1.24
Expired	(262,734)	1.49
Forfeited	(312,066)	1.60
Outstanding, April 30, 2018	2,811,600	1.83
Exercised	(217,984)	1.38
Expired	(977,934)	2.68
Forfeited	(30,932)	1.52
Outstanding, October 31, 2018	1,584,750	\$ 1.37

The following table summarizes information about the options outstanding and exercisable at October 31, 2018.

Range of Exercise Prices (CAD)	Number Outstanding	Weighted Average Remaining Life (years)	Weighted Average Exercise Price (CAD)	Number Exercisable
\$0.65 - \$0.75	400,250	0.70	\$ 0.69	400,250
\$1.04 - \$1.73	954,100	2.44	1.35	859,041
\$2.26 - \$2.82	230,400	1.52	2.60	230,400
	1,584,750	1.87	\$ 1.37	1,489,691

Notes to the Condensed Interim Consolidated Financial Statements

For the three and six months ended October 31, 2018 and 2017

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit) (continued)

(b) Stock options (continued)

The number of options exercisable at October 31, 2018 was 1,489,691 (2017 - 2,335,211) with a weighted average exercise price of CAD\$1.35 (2017 - CAD\$1.93).

The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model. During the six months ended October 31, 2018 and 2017, no stock options were granted.

(c) Restricted stock units

The Company's long term incentive plan allows for the reservation of a number of common shares not to exceed 10% of the Company's issued and outstanding common shares on an undiluted basis less the number of common shares reserved under the Company's amended stock option plan. The Company may grant restricted stock units ("RSUs") to directors, officers, employees, and consultants.

During the six months ended October 31, 2018 1,883,600 RSUs were granted (2017 - Nil). The RSUs vest over a period of six months to three years. The Company estimates the fair value of RSUs based on the market price of the underlying stock on the date of grant.

	Number of restricted stock units	Weighted average grant date fair value (USD)
Outstanding, April 30, 2017	534,179	\$ 1.19
Forfeited	(5,599)	1.11
Outstanding, April 30, 2018	528,580	1.19
Granted	1,883,600	2.53
Exercised	(41,666)	1.22
Forfeited	(9,566)	0.98
Outstanding, October 31, 2018	2,360,948	\$ 2.26

(d) Deferred share units

The Company's deferred share unit plan limits the maximum number of Common Shares issuable pursuant to outstanding deferred share units ("DSUs") at any time to 5% of the aggregate number of issued and outstanding Common Shares, provided that the combined maximum number of Common Shares issuable by the Company pursuant to outstanding DSUs and all of its other security based compensation arrangements may not exceed 10% of the Common Shares outstanding from time to time. The Company may grant DSUs to directors.

During the six months ended October 31, 2018 145,648 DSUs were granted (2017 - Nil). The DSUs fully vest at grant date. The Company estimates the fair value of DSUs based on the market price of the underlying stock on the date of grant.

	Number of deferred share units	Weighted average grant date fair value (USD)
Outstanding, April 30, 2018 and 2017	-	\$ -
Granted	145,648	2.53
Outstanding, October 31, 2018	145,648	\$ 2.53

Notes to the Condensed Interim Consolidated Financial Statements

For the three and six months ended October 31, 2018 and 2017

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit) (continued)

(e) Warrant liability

The following table summarizes the changes in liability-classified common share purchase warrants outstanding.

	Number of warrants	Weighted average exercise price (CAD)	Liability amount
Outstanding, April 30, 2017	9,000,237	\$ 1.28	\$ 7,515
Issued in connection with private placements	9,843,165	1.75	4,793
Issued in connection with prospectus offering	2,552,489	2.05	751
Expired	(2,048,640)	1.70	-
Revaluation of warrant liability	-	-	(4,246)
Outstanding, April 30, 2018	19,347,251	1.57	8,813
Issued in connection with Third Eye loan	3,500,000	1.40	1,419
Issued in connection with private placement	5,201,608	3.00	6,314
Exercised	(529,592)	0.90	(1,039)
Revaluation of warrant liability	-	-	30,969
Outstanding, October 31, 2018	27,519,267	\$ 1.83	\$ 46,476

The following table summarizes information about liability-classified warrants outstanding and exercisable at October 31, 2018.

Exercise Price (CAD)	Number Outstanding	Weighted Average Remaining Life (years)	Weighted Average Exercise Price (CAD)
\$0.75 - \$0.90	5,000,000	0.79	\$ 0.75
\$1.40 - \$1.64	10,209,395	2.85	1.53
\$2.00 - \$2.67	7,108,264	2.42	2.17
\$3.00	5,201,608	2.83	3.00
	27,519,267	2.36	\$ 1.83

Under IFRS, the prescribed accounting treatment for warrants, with an exercise price denominated in a foreign currency, is to treat these warrants as a liability measured at fair value with subsequent changes in fair value each reporting period accounted for through profit or loss. The initial fair value of these warrants is determined using the Black Scholes option pricing model.

The Company's warrants summarized above satisfy liability classification requirements and are exercisable at any time and thus the value of these warrants are presented as a current liability on the consolidated statement of financial position. As these warrants are exercised, the fair value of the recorded warrant liability on date of exercise is included in share capital along with the proceeds from the exercise. If these warrants expire, the related decrease in warrant liability is recognized in profit or loss, as part of the change in fair value of warrant liability.

During the year ended April 30, 2018, 12,395,654 liability-classified warrants were issued. Of the total, 2,552,489 warrants were issued on June 20, 2017 in connection with the prospectus offering discussed in Note 7 (a), and were listed for trading. The market value of these listed warrants represents a Level 1 input in the fair value hierarchy, and is used to value these warrants at each reporting period. As at October 31, 2018, the fair value of these listed warrants was CAD\$2.55 per warrant for a total value of \$4.945 million (April 30, 2018 - CAD\$0.68 per warrant for a total value of \$1.352 million).

An additional 9,843,165 warrants were issued in connection with the private placements completed on June 20, 2017 (2,951,313 warrants issued to Eastern and Hepalink), on September 8, 2017 (1,709,372 warrants issued), on December 1, 2017 (5,000,023 warrants issued to Hepalink) and on April 12, 2018 (182,457 warrants issued) and are unlisted. The warrants issued on June 20, 2017 have the same intrinsic factors as the listed warrants issued on June 20, 2017, and the fair value per listed warrant, described above, has been used to value the June 20, 2017 unlisted warrants, less an illiquidity discount of 13.75%, at the initial issue date and at each reporting period. This represents a level 3 input in the fair value hierarchy.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and six months ended October 31, 2018 and 2017

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit) (continued)

(e) Warrant liability (continued)

The fair value of the remaining warrants is determined using the Black Scholes option pricing model at initial issue date and at each reporting period.

The change in fair value of the liability-classified warrants is based on several factors including changes in the market price of our shares, as well as decreases in the remaining terms of the various series of warrants, and changes in estimated future volatility of our common shares. The fair value of the warrants is subject to significant volatility.

During the six months ended October 31, 2018, 3,500,000 warrants were issued in connection with the Third Eye Loan and 5,201,608 warrants were issued in connection with the August 2018 private placement. The weighted average fair value of the warrants issued during the six months ended October 31, 2018 was \$0.89 per warrant, using the Black-Scholes option pricing model and the following assumptions for the two separate issuances:

	Issued in connection with Third Eye loan	Issued in connection with private placement
Number of warrants issued	3,500,000	5,201,608
Risk-free interest rate	2.1%	2.2%
Expected life	3.0 years	3.0 years
Expected volatility	69%	73%
Share price at grant date (CAD)	\$1.33	\$3.12

(f) Equity-classified warrants

On June 20, 2017 and December 1, 2017, the Company issued 178,674 warrants and 1,342,593 warrants, respectively, to financial advisors involved with the June 20, 2017 prospectus offering and December 1, 2017 private placement described in Note 7 (a). These warrants are classified as an equity instrument and accounted for under IFRS 2 – *Share-Based Payments* as they are a form of compensation for services rendered. Due to the equity classification, the warrants will not be revalued each reporting period. Each warrant issued on June 20, 2017 is exercisable at a price of CAD\$2.05 for a period of two years and each warrant issued on December 1, 2017 is exercisable at a price of CAD\$1.62 for a period of four years.

There were no equity-classified warrants issued during the six months ended October 31, 2018. The weighted average fair value of the warrants issued during the six months ended October 31, 2017 was \$0.23 per warrant using the Black-Scholes option pricing model with the following weighted average assumptions:

	2017
Risk-free interest rate	1.0%
Expected life	2.0 years
Expected volatility	70%

The following table summarizes information about the equity classified warrants outstanding and exercisable at October 31, 2018.

Exercise Price (CAD)	Number Outstanding and Exercisable	Weighted Average Remaining Life (years)
\$1.62	1,342,593	3.09
\$2.05	7,125	0.64
\$2.67	331,750	1.72
	1,681,468	2.81

Notes to the Condensed Interim Consolidated Financial Statements

For the three and six months ended October 31, 2018 and 2017

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

7. Shareholders' equity (deficit) (continued)

(g) Per share amounts

The basic and diluted earnings (loss) per share have been calculated based on the weighted average shares outstanding:

	Three months ended October 31,		Six months ended October 31,	
	2018	2017	2018	2017
Weighted average common shares outstanding - basic and diluted	185,185,837	113,196,482	181,225,692	110,687,997

The effect of any potential exercise of stock options, restricted stock units and warrants outstanding is excluded from the calculation of diluted loss per share in periods where the effect would be anti-dilutive.

8. Expenses by nature

Presentation of expenses is based on the function of each expense. The following details highlight certain components of the research and development and general and administrative expenses classified by nature. Remaining research and development and general and administrative expenses include personnel costs and expenses paid to third parties.

	Three months ended October 31,		Six months ended October 31,	
	2018	2017	2018	2017
Included in research and development expenses:				
Share-based payment transaction costs	\$ 307	\$ 45	\$ 320	\$ 102
Amortization and depreciation	62	60	123	137
Impairment of intangible assets	-	294	-	294
Included in general and administrative expenses:				
Share-based payment transaction costs	\$ 1,011	\$ 54	\$ 1,049	\$ 53
Amortization and depreciation	25	26	49	53

9. Commitments

As at October 31, 2018, the Group is committed to expenditures over the next twelve months of \$7.2 million (2017 - \$7.0 million) under various research and development contracts.

As at October 31, 2018, the Group is also party to cancellable agreements with a contract research organization and a central laboratory conducting the BETonMACE trial. Corresponding estimated aggregate expenditures over the next twelve months total approximately \$15 - 20 million (2017 - \$15 - 20 million).

As at October 31, 2018, the Group is also committed to operating lease payments for office and laboratory premises as follows:

	2018	2017
Less than 1 year	\$ 689	\$ 658
Between 1 and 5 years	2,052	2,374
More than 5 years	33	441
	\$ 2,774	\$ 3,473

Zenith agreed to pay the Company for its proportionate share of operating lease payments and operating costs for office and laboratory of an estimated \$0.2 million and \$0.1 million, respectively, for the next twelve months.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and six months ended October 31, 2018 and 2017

(unaudited)

(amounts in thousands of US dollars, except for number of shares)

10. Subsequent event

Private placement

Subsequent to October 31, 2018, the Company closed a private placement and issued 4.5 million units at a price of CAD\$3.00 per unit for gross proceeds of \$10.3 million (CAD\$13.5 million). Each unit was comprised of one common share and one-half of a common share purchase warrant. Each warrant is exercisable at a price of CAD\$3.10 per share for a period of three years from the closing of the private placement.

The Company repaid \$5.15 million of the Third Eye Loan corresponding to 50% of the net cash proceeds from the \$10.3 million private placement subsequent to October 31, 2018.